Martin J Landray

List of Publications by Year
in descending order

119 papers	32,227 citations	53660 45 h-index	21474 114 g-index
134 all docs	134 docs citations	134 times ranked	48822 citing authors

#	Article	IF	Citations
1	Improved clinical investigation and evaluation of high-risk medical devices: the rationale and objectives of CORE-MD (Coordinating Research and Evidence for Medical Devices). European Heart Journal Quality of Care & Clinical Outcomes, 2022, 8, 249-258.	1.8	13
2	Development and evaluation of rapid data-enabled access to routine clinical information to enhance early recruitment to the national clinical platform trial of COVID-19 community treatments. Trials, 2022, 23, 62.	0.7	8
3	Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease. European Heart Journal, 2022, 43, 1416-1424.	1.0	27
4	Dexamethasone in Hospitalized Patients with Covid-19. New England Journal of Medicine, 2021, 384, 693-704.	13.9	8,063
5	Accelerometer-measured physical activity and functional behaviours among people on dialysis. CKJ: Clinical Kidney Journal, 2021, 14, 950-958.	1.4	8
6	Conventional and Genetic Evidence on the Association between Adiposity and CKD. Journal of the American Society of Nephrology: JASN, 2021, 32, 127-137.	3.0	39
7	Potential health and economic impacts of dexamethasone treatment for patients with COVID-19. Nature Communications, 2021, 12, 915.	5.8	40
8	Impact of the COVID-19 pandemic on the detection and management of colorectal cancer in England: a population-based study. The Lancet Gastroenterology and Hepatology, 2021, 6, 199-208.	3.7	244
9	Realising the full potential of data-enabled trials in the UK: a call for action. BMJ Open, 2021, 11, e043906.	0.8	23
10	Tocilizumab in COVID-19 therapy: who benefits, and how? â€“ Authors' reply. Lancet, The, 2021, 398, 300.	6.3	3
11	Making trials part of good clinical care: lessons from the RECOVERY trial. Future Healthcare Journal, 2021, 8, e243-e250.	0.6	32
12	Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19. JAMA - Journal of the American Medical Association, 2021, 326, 499.	3.8	498
13	Comparison of the Accuracy and Completeness of Records of Serious Vascular Events in Routinely Collected Data vs Clinical Trialâ€“Adjudicated Direct Follow-up Data in the UK. JAMA Network Open, 2021, 4, e2139748.	2.8	15
14	Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. New England Journal of Medicine, 2020, 383, 2030-2040.	13.9	1,013
15	Lopinavirâ€“ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet, The, 2020, 396, 1345-1352.	6.3	569
16	Weighing the Benefits and Risks of Proliferating Observational Treatment Assessments. JAMA - Journal of the American Medical Association, 2020, 324, 625.	3.8	40
17	Cross-sectional associations between central and general adiposity with albuminuria: observations from 400,000 people in UK Biobank. International Journal of Obesity, 2020, 44, 2256-2266.	1.6	9
18	Independent risk factors for simvastatin-related myopathy and relevance to different types of muscle symptom. European Heart Journal, 2020, 41, 3336-3342.	1.0	27

#	Article	IF	Citations
19	COVID-19 pandemic and admission rates for and management of acute coronary syndromes in England. Lancet, The, 2020, 396, 381-389.	6.3	521
20	Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19. JAMA - Journal of the American Medical Association, 2020, 324, 1330.	3.8	1,855
21	Corticosteroid therapy for critically ill patients with COVID-19: A structured summary of a study protocol for a prospective meta-analysis of randomized trials. Trials, 2020, 21, 734.	0.7	30
22	Regulating drugs, medical devices, and diagnostic tests in the European Union: early lessons from the COVID-19 pandemic?. European Heart Journal, 2020, 41, 2140-2144.	1.0	5
23	The Magic of Randomization versus the Myth of Real-World Evidence. New England Journal of Medicine, 2020, 382, 674-678.	13.9	296
24	Impact of ADCY9 Genotype on Response to Anacetrapib. Circulation, 2019, 140, 891-898.	1.6	34
25	Serious Adverse Effects of Extended-release Niacin/Laropiprant: Results From the Heart Protection Study 2â€“Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) Trial. Clinical Therapeutics, 2019, 41, 1767-1777.	1.1	12
26	Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet, The, 2019, 393, 407-415.	6.3	512
27	Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease. Kidney International, 2019, 96, 170-179.	2.6	13
28	Assessment of Vascular Event Prevention and Cognitive Function Among Older Adults With Preexisting Vascular Disease or Diabetes. JAMA Network Open, 2019, 2, e190223.	2.8	16
29	Physical activity, sleep and cardiovascular health data for 50,000 individuals from the MyHeart Counts Study. Scientific Data, 2019, 6, 24.	2.4	43
30	Investigating modifications to participant information materials to improve recruitment into a large randomized trial. Trials, 2019, 20, 681.	0.7	3
31	Relationship of Estimated GFR and Albuminuria to Concurrent Laboratory Abnormalities: An Individual Participant Data Meta-analysis in a Global Consortium. American Journal of Kidney Diseases, 2019, 73, 206-217.	2.1	49
32	Prognostic utility of estimated albumin excretion rate in chronic kidney disease: results from the Study of Heart and Renal Protection. Nephrology Dialysis Transplantation, 2018, 33, gfw396.	0.4	6
33	A decade of the Clinical Trials Transformation Initiative: What have we accomplished? What have we learned?. Clinical Trials, 2018, 15, 5-12.	0.7	11
34	2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. Circulation, 2018, 137, 961-972.	1.6	368
35	Declining comorbidity-adjusted mortality rates in English patients receiving maintenance renal replacement therapy. Kidney International, 2018, 93, 1165-1174.	2.6	21
36	Increasing the use of mobile technologyâ€“derived endpoints in clinical trials. Clinical Trials, 2018, 15, 313-315.	0.7	14

#	Article	IF	Citations
37	Impact of CKD on Household Income. Kidney International Reports, 2018, 3, 610-618.	0.4	25
38	Campath, calcineurin inhibitor reduction, and chronic allograft nephropathy (the 3C Study) â€“ results of a randomized controlled clinical trial. American Journal of Transplantation, 2018, 18, 1424-1434.	2.6	18
39	Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation. Kidney International, 2018, 93, 1000-1007.	2.6	32
40	Trends in the Incidence and Recurrence of Inpatient-Treated Spontaneous Pneumothorax, 1968-2016. JAMA - Journal of the American Medical Association, 2018, 320, 1471.	3.8	107
41	The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study. CKJ: Clinical Kidney Journal, 2018, 11, 749-761.	1.4	196
42	Impact of Apolipoprotein(a) Isoform Size on Lipoprotein(a) Lowering in the HPS2-THRIVE Study. Circulation Genomic and Precision Medicine, 2018, 11, e001696.	1.6	65
43	Fibroblast Growth Factor-23 and Risks of Cardiovascular and Noncardiovascular Diseases: A Meta-Analysis. Journal of the American Society of Nephrology: JASN, 2018, 29, 2015-2027.	3.0	140
44	Use of Mobile Devices to Measure Outcomes in Clinical Research, 2010â€“2016: A Systematic Literature Review. Digital Biomarkers, 2018, 2, 11-30.	2.2	70
45	Effects of Sacubitril/Valsartan Versus Irbesartan in Patients With Chronic Kidney Disease. Circulation, 2018, 138, 1505-1514.	1.6	145
46	Biliary Tract and Liver Complications in Polycystic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2017, 28, 2738-2748.	3.0	19
47	Improving public health by improving clinical trial guidelines and their application. European Heart Journal, 2017, 38, 1632-1637.	1.0	19
48	Evidence for Reverse Causality in the Association Between Blood Pressure and Cardiovascular Risk in Patients With Chronic Kidney Disease. Hypertension, 2017, 69, 314-322.	1.3	30
49	Feasibility of Obtaining Measures of Lifestyle From a Smartphone App. JAMA Cardiology, 2017, 2, 67.	3.0	207
50	Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease. New England Journal of Medicine, 2017, 377, 1217-1227.	13.9	780
51	Use of Causal Diagrams to Inform the Design and Interpretation of Observational Studies: An Example from the Study of Heart and Renal Protection (SHARP). Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 546-552.	2.2	41
52	The Association of Serum Free Light Chains With Mortality and Progression to End-Stage Renal Disease in Chronic Kidney Disease: Systematic Review and Individual Patient Data Meta-analysis. Mayo Clinic Proceedings, 2017, 92, 1671-1681.	1.4	12
53	A policy model of cardiovascular disease in moderate-to-advanced chronic kidney disease. Heart, 2017, 103, 1880-1890.	1.2	21
54	Effect of Processing Delay and Storage Conditions on Urine Albumin-to-Creatinine Ratio. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 1794-1801.	2.2	22

#	Article	IF	Citations
55	Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials. Lancet Diabetes and Endocrinology,the, 2016, 4, 829-839.	5.5	234
56	Effects of Vascular and Nonvascular Adverse Events and of Extended-Release Niacin With Laropiprant on Health and Healthcare Costs. Circulation: Cardiovascular Quality and Outcomes, 2016, 9, 348-354.	0.9	8
57	Smoking and Adverse Outcomes in Patients With CKD: The Study of Heart and Renal Protection (SHARP). American Journal of Kidney Diseases, 2016, 68, 371-380.	2.1	57
58	Enhancing clinical evidence by proactively building quality into clinical trials. Clinical Trials, 2016, 13, 439-444.	0.7	45
59	Impact of Educational Attainment on Health Outcomes in Moderate to Severe CKD. American Journal of Kidney Diseases, 2016, 67, 31-39.	2.1	42
60	Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the StudyÂofÂHeartÂand Renal Protection (SHARP). American Journal of Kidney Diseases, 2016, 67, 576-584.	2.1	19
61	Improving clinical trials for cardiovascular diseases: a position paper from the Cardiovascular Round Table of the European Society of Cardiology. European Heart Journal, 2016, 37, 747-754.	1.0	62
62	Methodology for UK recruitment into a large-scale international clinical trial. Trials, 2015, 16, .	0.7	0
63	How was it for you? - obtaining feedback from staff at study sites for the HPS2-thrive trial. Trials, 2015, 16, .	0.7	0
64	Challenges of linking to routine healthcare records in UK Biobank. Trials, 2015, 16, .	0.7	10
65	Investigating possible fraudulent activity at a research site. Trials, 2015, 16, .	0.7	0
66	Quality by design: using intelligent forms to ensure study protocol compliance and participant safety. Trials, 2015, 16, .	0.7	0
67	Can vascular mortality be reliably ascertained from the underlying cause of death recorded on a medical death certificate? Evidence from 2800 adjudicated heart protection study (HPS) deaths. Trials, 2015, 16, .	0.7	1
68	What is the impact of chronic kidney disease stage and cardiovascular disease on the annual cost of hospital care in moderate-to-severe kidney disease?. BMC Nephrology, 2015, 16, 65.	0.8	82
69	UK Biobank: An Open Access Resource for Identifying the Causes of a Wide Range of Complex Diseases of Middle and Old Age. PLoS Medicine, 2015, 12, e1001779.	3.9	6,753
70	A Meta-analysis of the Association of Estimated GFR, Albuminuria, Diabetes Mellitus, and Hypertension With Acute Kidney Injury. American Journal of Kidney Diseases, 2015, 66, 602-612.	2.1	210
71	A Meta-analysis of the Association of Estimated GFR, Albuminuria, Age, Race, and Sex With Acute Kidney Injury. American Journal of Kidney Diseases, 2015, 66, 591-601.	2.1	138
72	Neprilysin inhibition in chronic kidney disease. Nephrology Dialysis Transplantation, 2015, 30, 738-743.	0.4	80

#	Article	IF	Citations
73	Use of gel-based separator tubes to stabilise phosphate in mailed blood samples. Clinica Chimica Acta, 2015, 439, 112-114.	0.5	0
74	Evidence for the Prevention and Treatment of Stroke in Dialysis Patients. Seminars in Dialysis, 2015, 28, 35-47.	0.7	49
75	Results of a Large Randomized Controlled Trial of Alemtuzumab-Versus Basiliximab-Based Induction Therapy in Kidney Transplantation.. Transplantation, 2014, 98, 155.	0.5	0
76	Niacin for Reduction of Cardiovascular Risk. New England Journal of Medicine, 2014, 371, 1940-1944.	13.9	7
77	Effects of Lowering LDL Cholesterol on Progression of Kidney Disease. Journal of the American Society of Nephrology: JASN, 2014, 25, 1825-1833.	3.0	142
78	Evaluating the Contribution of the Cause of Kidney Disease to Prognosis in CKD: Results From the Study of Heart and Renal Protection (SHARP). American Journal of Kidney Diseases, 2014, 64, 40-48.	2.1	55
79	Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): a randomised trial. Lancet, The, 2014, 384, 1684-1690.	6.3	124
80	Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients. New England Journal of Medicine, 2014, 371, 203-212.	13.9	1,367
81	The Effect of Lowering LDL Cholesterol on Vascular Access Patency. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 914-919.	2.2	19
82	Campath, calcineurin inhibitor reduction and chronic allograft nephropathy (3C) study: background, rationale, and study protocol. Transplantation Research, 2013, 2, 7.	1.5	21
83	Randomized Clinical Trials â€" Removing Unnecessary Obstacles. New England Journal of Medicine, 2013, 369, 1061-1065.	13.9	103
84	HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. European Heart Journal, 2013, 34, 1279-1291.	1.0	581
85	Randomized Clinical Trials â€" Removing Obstacles. New England Journal of Medicine, 2013, 369, 2268-2269.	13.9	8
86	Clinical Trials: Rethinking How We Ensure Quality. Drug Information Journal, 2012, 46, 657-660.	0.5	16
87	Cardiovascular Aspects of Kidney Disease. , 2012, , 2059-2080.		5
88	Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. Kidney International, 2011, 79, 1331-1340.	2.6	609
89	The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet, The, 2011, 377, 2181-2192.	6.3	2,087
90	Benefits of lowering cholesterol in chronic kidney disease â€" Authors' reply. Lancet, The, 2011, 378, 1377-1378.	6.3	1

#	Article	IF	Citations
91	Estimated Glomerular Filtration Rate and the Risk of Major Vascular Events and All-Cause Mortality: A Meta-Analysis. PLoS ONE, 2011, 6, e25920.	1.1	70
92	Serum Free Light Chains and the Risk of ESRD and Death in CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 2829-2837.	2.2	35
93	Prediction of ESRD and Death Among People With CKD: The Chronic Renal Impairment in Birmingham (CRIB) Prospective Cohort Study. American Journal of Kidney Diseases, 2010, 56, 1082-1094.	2.1	144
94	Cystatin C and risk of vascular and nonvascular mortality: a prospective cohort study of older men. Journal of Internal Medicine, 2010, 268, 145-154.	2.7	22
95	LIPIDS IN CHRONIC KIDNEY DISEASE. Journal of Renal Care, 2010, 36, 27-33.	0.6	14
96	Reassuring results with regard to the effect of donor nephrectomy on cardiovascular outcomes. Nature Reviews Nephrology, 2009, 5, 126-127.	4.1	1
97	Dual blockade of the renin-angiotensin system: are two better than one?. Nephrology Dialysis Transplantation, 2009, 24, 3602-3607.	0.4	8
98	Analyses of Cancer Data from Three Ezetimibe Trials. New England Journal of Medicine, 2008, 359, 1357-1366.	13.9	230
99	Commentary: Controversies in NICE guidance on chronic kidney disease. BMJ: British Medical Journal, 2008, 337, a1793-a1793.	2.4	5
100	A Practical Method of Measuring Glomerular Filtration Rate by Iohexol Clearance Using Dried Capillary Blood Spots. Nephron Clinical Practice, 2007, 106, c104-c112.	2.3	24
101	Cross-Sectional Analysis of Abnormalities of Mineral Homeostasis, Vitamin D and Parathyroid Hormone in a Cohort of Pre-Dialysis Patients. Nephron Clinical Practice, 2007, 107, c109-c116.	2.3	42
102	CARDIOVASCULAR AND SURVIVAL PARADOXES IN DIALYSIS PATIENTS: Misleading Associations between Cholesterol and Vascular Outcomes in Dialysis Patients: The Need for Randomized Trials. Seminars in Dialysis, 2007, 20, 498-503.	0.7	23
103	The Second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: A Randomized Controlled Study of the Biochemical Safety and Efficacy of Adding Ezetimibe to Simvastatin as Initial Therapy Among Patients With CKD. American Journal of Kidney Diseases, 2006, 47, 385-395.	2.1	104
104	Which cardiovascular risk factors matter in chronic kidney disease?. Nephrology Dialysis Transplantation, 2006, 22, 9-11.	0.4	18
105	Dose-dependent effects of folic acid on blood concentrations of homocysteine: a meta-analysis of the randomized trials. American Journal of Clinical Nutrition, 2005, 82, 806-812.	2.2	400
106	First United Kingdom Heart and Renal Protection (UK-HARP-I) study: Biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. American Journal of Kidney Diseases, 2005, 45, 473-484.	2.1	184
107	Testing the practical aspects of therapeutics by objective structured clinical examination. Journal of Clinical Pharmacy and Therapeutics, 2004, 29, 263-266.	0.7	16
108	Inflammation, endothelial dysfunction, and platelet activation in patients with chronic kidney disease: the chronic renal impairment in Birmingham (CRIB) study. American Journal of Kidney Diseases, 2004, 43, 244-253.	2.1	272

#	Article	IF	Citations
109	Statin therapy in kidney disease populations: potential benefits beyond lipid lowering and the need for clinical trials. Current Opinion in Nephrology and Hypertension, 2004, 13, 601-605.	1.0	15
110	Homocysteine, renal function, and risk of cardiovascular disease. Kidney International, 2003, 63, S131-S133.	2.6	37
111	The cardioprotective role of beta-blockers in patients with diabetes mellitus. Journal of Clinical Pharmacy and Therapeutics, 2002, 27, 233-242.	0.7	14
112	A randomized double-blind placebo-controlled trial of the effect of homocysteine-lowering therapy with folic acid on endothelial function in patients with coronary artery disease. Journal of the American College of Cardiology, 2001, 37, 1858-1863.	1.2	82
113	Renal function: an emerging risk factor for cardiovascular disease?. Evidence-based Cardiovascular Medicine, 2001, 5, 32-33.	0.0	3
114	Epidemiological evaluation of known and suspected cardiovascular risk factors in chronic renal impairment. American Journal of Kidney Diseases, 2001, 38, 537-546.	2.1	97
115	Adverse effects of drugs on the development of ischaemic heart disease. Adverse Drug Reaction Bulletin, 2000, 203, 775-778.	0.6	0
116	A pilot study of streptokinase-induced endothelial injury and platelet activation following acute myocardial infarction. Journal of Internal Medicine, 2000, 248, 316-318.	2.7	15
117	Association between elevated plasma fibrinogen and the small, dense low-density lipoprotein phenotype among postmenopausal women. American Journal of Cardiology, 2000, 86, 126.	0.7	8
118	Lipid-lowering drugs and homocysteine. Lancet, The, 1999, 353, 1974-1975.	6.3	23
119	Oxidative stress after thrombolysis. Lancet, The, 1998, 352, 960.	6.3	9